ReviewAnnals of translational medicine2020
An update on chronic lung allograft dysfunction.
Review in Annals of translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinical applications of mesenchymal stromal cell-based therapies for pulmonary diseases: An Update and Concise Review.International journal of medical sciences · 2021Pooled it
- Phenotyping immune sensitization reveals pattern-based association with post-lung transplant complications.JHLT open · 2026Article
- Assessing health-related quality of life in patients with interstitial lung diseases with and without lung transplantation using the GR-Scale.BMC pulmonary medicine · 2026Article
- Chronic Lung Allograft Dysfunction in Patients Receiving Lung Transplantation for COVID-19 ARDS.Transplant international : official journal of the European Society for Organ Transplantation · 2025Article
- Radiomics of spinal muscles: toward a radiological biomarker for allograft rejection in lung transplant.La Radiologia medica · 2023Article
- Molecular Profiling of Tissue Samples with Chronic Rejection from Patients with Chronic Lung Allograft Dysfunction: A Pilot Study in Cystic Fibrosis Patients.Biomolecules · 2023Article
- The role of lung-restricted autoantibodies in the development of primary and chronic graft dysfunction.Frontiers in transplantation · 2023Review
- Characterization of chronic lung allograft dysfunction phenotypes using spectral and intrabreath oscillometry.Frontiers in physiology · 2022Article
- An update on current treatment strategies for managing bronchiolitis obliterans syndrome after lung transplantation.Expert review of respiratory medicine · 2021Review
- Immune Checkpoints Expression in Chronic Lung Allograft Rejection.Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic lung allograft dysfunction (CLAD) remains a significant challenge and the major determinant of morbidity and mortality post lung transplantation (LTx). The definition of CLAD has evolved significantly over the last ten years, reflecting better understanding of pathophysiology and different phenotypes. While there is an agreed consensus approach to CLAD, questions remain regarding the limitations of lung function parameters as well as the role of imaging and histopathology. Here we present a current snapshot of the definition of CLAD, its evolution and future directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.